跳至主要内容
临床试验/NCT07750899
NCT07750899已完成不适用

The Effect of Standardized Withania Somnifera Extract on Endocrine, Metabolic, and Psychometric Parameters, in Women With Polyendocrine Metabolic Ovarian Syndrome: a Randomized Active-controlled Trial

Medical University of Lodz1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2025年1月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
1
主要终点
Beck Depression Inventory (BDI-II)

研究概览

简要总结

The objective of this study is to ascertain the impact of a standardized Withania somnifera extract on endocrine, metabolic, and psychometric parameters in women diagnosed with polyendocrine metabolic ovarian syndrome. The assessment will encompass a range of parameters to determine the severity of depression, stress levels, the quality of sleep, blood pressure, body mass index, and body composition. Additionally, biochemical, metabolic, and endocrine blood parameters in serum will be analysed.

The trial's findings may yield a safe and easy-to-use method of adjunctive treatment that could complement therapy in patients with polycystic ovary syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • a diagnosis confirming the presence of polycystic ovary syndrome,
  • age falling within the closed range of 18-45 years,
  • absence of pregnancy confirmed by measurement of human chorionic gonadotrophin (β-hCG) levels in serum or urine, or by a gynaecological examination,
  • not currently breastfeeding,
  • no implanted metallic devices, such as: prostheses, pacemakers, defibrillators, stents, or metallic sutures in the heart or blood vessels,
  • no diagnosed epilepsy and no history of epileptic seizures,
  • not taking anti-epileptic medication,
  • not taking benzodiazepine-based sedatives,
  • not taking medicines containing metformin (e.g. Avamina, Formetic, Glucophage, Metformax, Siofor),
  • not taking preparations containing oestrogens and/or progestogens,
  • not taking dietary supplements.

排除标准

  • no diagnosis confirming the presence of polycystic ovary syndrome,
  • age under 18 or over 45,
  • pregnancy confirmed by measurement of human chorionic gonadotrophin (β-hCG) levels in serum or urine, or by a gynaecological examination,
  • currently breastfeeding,
  • having implanted metallic devices, such as: a prosthesis, a pacemaker, a defibrillator, a stent, or a metallic suture in the heart or a blood vessel,
  • diagnosed epilepsy or a history of epileptic seizures,
  • taking anti-epileptic medication,
  • taking benzodiazepine-based sedatives,
  • taking medicines containing metformin (e.g. Avamina, Formetic, Glucophage, Metformax, Siofor),
  • taking preparations containing oestrogens and/or progestogens,
  • poor general health, severe generalised and systemic diseases, including liver and kidney failure, malabsorption syndromes,
  • allergy to plants of the nightshade family,
  • taking dietary supplements.

研究组 & 干预措施

Control group

Active Comparator

Cholecalciferol, folic acid, and 5-methyltetrahydrofolate

干预措施: Active comparator (Dietary Supplement)

Treatment Group

Experimental

Withania somnifera, cholecalciferol, folic acid, and 5-methyltetrahydrofolate

干预措施: Withania somnifera (Dietary Supplement)

结局指标

主要结局

Beck Depression Inventory (BDI-II)

时间窗: Baseline, 3 months, 6 months

The Beck Depression Inventory (BDI-II) is a validated 21-item questionnaire assessing symptoms of depression. It includes 21 items, each containing four options, scored on a scale of 0 to 3, where 0 indicates the absence of a symptom and 3 its greatest intensity. Higher scores indicate greater symptom severity (worse outcome). This outcome measures the mean change from baseline in BDI-II total score, where a reduction in score indicates improvement in psychological symptoms.

次要结局

  • Complete blood count parameters: white blood cell count (WBC), red blood cell count (RBC), haemoglobin, haematocrit, and platelets concentration(Baseline, 3 months, 6 months)
  • Perceived Stress Scale (PSS-10)(Baseline, 3 months, 6 months)
  • Pittsburgh Sleep Quality Index (PSQI)(Baseline, 3 months, 6 months)
  • International Physical Activity Questionnaire - Short Form (IPAQ-SH)(Baseline, 3 months, 6 months)
  • Food Frequency Questionnaire (FFQ-6)(Baseline, 3 months, 6 months)
  • Concentration of metabolic and inflammatory parameters: fasting glucose, fasting insulin, C-reactive protein (CRP), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and alanine aminotransferase (ALT) blood concentration(Baseline, 3 months, 6 months)
  • Concentration of endocrine parameters: total testosterone, prolactin, oestrogen, sex hormone-binding globulin (SHBG), luteinising hormone (LH), follicle-stimulating hormone (FSH), cortisol, and dehydroepiandrosterone sulphate (DHEA-S) blood concentration(Baseline, 3 months, 6 months)
  • Blood pressure parameters: systolic (SBP) and diastolic (DBP) blood pressure(Baseline, 3 months, 6 months)
  • Body composition: skeletal muscle mass, and fat mass(Baseline, 3 months, 6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验